<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662113</url>
  </required_header>
  <id_info>
    <org_study_id>DomperidoneVCE</org_study_id>
    <nct_id>NCT03662113</nct_id>
  </id_info>
  <brief_title>Effect of Domperidone on Completion Rate of Vedio Capsule Endoscopy</brief_title>
  <official_title>Effect of Domperidone on Completion Rate of Vedio Capsule Endoscopy: a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Video capsule endoscopy (VCE) has become an established technique to investigate the presence
      of small bowel pathology. But the limited battery life of capsules can lead to incomplete
      small bowel visualization. There is a rationale to use prokinetic agents prior to VCE reduce
      the chances of an incomplete small bowel examination via decrease gastric transit time (GTT).
      Investigators are aimed to prospectively compare the completion rate of VCE in pediatric
      patients receiving prokinetic with those receiving no prokinetic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible children were randomly divided into two groups: domperidone prior to VCE and water
      prior to VCE. The primary outcome measure was the completion rate. Secondary outcome measures
      included the GTT and SBTT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion rate of capsule endoscopy</measure>
    <time_frame>assessed through study completion, an average of 1 year</time_frame>
    <description>CE was considered complete when the cecum was reached within recording time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric transit time (GTT)</measure>
    <time_frame>assessed through study completion, an average of 1 year</time_frame>
    <description>The GTT was defined as the time, in minutes, from the first image of the stomach until the first image of the duodenum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>small bowel transit time (SBTT)</measure>
    <time_frame>assessed through study completion, an average of 1 year</time_frame>
    <description>The SBTT was defined as the passage time, in minutes, from the first image of the duodenum until the first image of the cecum.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Capsule Endoscopy</condition>
  <condition>Pediatric Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental: Domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5ml domperidone prior to VCE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: water</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5ml warm water prior to VCE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>5ml Domperidone prior to VCE</description>
    <arm_group_label>Experimental: Domperidone</arm_group_label>
    <other_name>simethicone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>water</intervention_name>
    <description>5ml water prior to VCE</description>
    <arm_group_label>Control: water</arm_group_label>
    <other_name>simethicone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indications of capsule endoscopy;

          -  Informed consent form obtained.

        Exclusion Criteria:

          -  Contraindication of capsule endoscopy;

          -  Domperidone allergy;

          -  Unwilling to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Huang, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital of Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's hospital of Fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mcfarlane M, Liu B, Nwokolo C. Domperidone prolongs oral to duodenal transit time in video capsule endoscopy. Eur J Clin Pharmacol. 2018 Apr;74(4):521-524. doi: 10.1007/s00228-017-2399-8. Epub 2017 Dec 8.</citation>
    <PMID>29222714</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Ying HUANG</investigator_full_name>
    <investigator_title>The director of gastroenterology of Children's Hospital of Fudan University</investigator_title>
  </responsible_party>
  <keyword>domperidone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Simethicone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

